

# PRESS RELEASE



August 23, 2022, Lund, Sweden

## **Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase**

**LUND, SWEDEN** – Immunovia today announced it will participate in Gilmartin Group's Emerging Growth Company Showcase on August 31, 2022.

Philipp Mathieu, CEO and President, and Jeff Borcharding, US CEO, are scheduled to present on Wednesday, August 31, 2022 at 9:00 am ET (15:00 pm CET).

A live and archived webcast will be available on the "Investors" section of the Immunovia website at <https://investor.immunovia.com/>.

### **For more information, please contact:**

Karin Almqvist Liwendahl

CFO

[karin.almqvist.liwendahl@immunovia.com](mailto:karin.almqvist.liwendahl@immunovia.com)

+46 70 911 56 08

### **About Immunovia**

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance.

Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: [www.immunoviainc.com](http://www.immunoviainc.com).

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit [www.immunovia.com](http://www.immunovia.com).